Research
Hormonal
SGLT2 inhibitors cause an acute, dose-dependent reduction in eGFR (~5 ml/min/1.73m2) and a ~30-40% reduction in albuminuria, which are protective renal hemodynamic effects rather than signs of kidney damage.
When you start an SGLT2 inhibitor, your eGFR (a measure of kidney function) may drop slightly at first. This is a normal, protective response where the kidney reduces its internal filtering pressure to prevent long-term damage. This acute drop is associated with a significant reduction in albuminuria (protein in urine) and long-term kidney protection.
GoodQualifiesHIGH confidence
SGLT2 inhibition is also associated with an acute, dose-dependent reduction in eGFR by ~5 ml/min/1.73m2 and ~30-40% reduction in albuminuria. These effects mirror pre-clinical observations suggesting that proximal tubular natriuresis activates renal tubuloglomerular feedback through increased macula densa sodium and chloride delivery, leading to afferent vasoconstriction.
Why this rating
Based on pre-clinical and clinical observations cited in the review.
Source
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
Hiddo J.L. Heerspink et al. · Circulation · 2016
DOI 10.1161/circulationaha.116.021887
narrative_reviewCited 1,329×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) reduce cardiovascular mortality, overall mortality, and heart failure hospitalizations in patients with type 2 diabetes and established cardiovascular disease, independent of glycemic control.Strong
- SGLT2 inhibitors lower blood pressure by approximately 4-6 mmHg systolic and 1-2 mmHg diastolic, primarily through plasma volume contraction and reduced arterial stiffness.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →